GlassScriptPhysician profile
Stephen A Bowser
NPI 1598737355
$4,058.46
in general payments reported to CMS, 2019-2025
21 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $155 · 2021: $105 · 2022: $758 · 2023: $579 · 2024: $1,504 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Travel and Lodging: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.55 |
| Travel and Lodging | $983.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,371.04 | 2019-2025 | Mitraclip, Triclip |
| Novartis Pharmaceuticals Corporation | $617.91 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $502.14 | 2019-2023 | Xarelto |
| Innovation Technologies INC | $295.59 | 2022-2025 | Irrisept |
| Pfizer INC. | $261.53 | 2019-2024 | |
| Amgen INC. | $250.51 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.98 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $99.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.66 | 2019-2023 | Andexxa |
| Regeneron Healthcare Solutions, INC. | $56.18 | 2019 | |
| Boston Scientific Corporation | $54.54 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $41.09 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.93 | 2024 | Lifevest |
| Biotronik INC. | $30.18 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $27.95 | 2021 | |
| Cardiva Medical, INC. | $24.92 | 2022 | |
| Gilead Sciences, INC. | $24.57 | 2019 | |
| Astellas Pharma US INC | $17.86 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.05 | 2020 | |
| Novo Nordisk INC | $13.95 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bowser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.